Skip to main content
. Author manuscript; available in PMC: 2016 Jun 1.
Published in final edited form as: Curr Hematol Malig Rep. 2015 Jun;10(2):158–166. doi: 10.1007/s11899-015-0248-3

Table 1.

FDA-approved and investigational BCR-ABL1 inhibitors targeting the kinase domain or the myristate pocket.

Inhibitor Chemical structure Binding site/
Inhibitor type		 Regulatory status/
approval
imatinib (Gleevec) graphic file with name nihms666383t1.jpg ATP-binding site/ATP-competitive FDA approved/Frontline therapy
nilotinib (Tasigna) graphic file with name nihms666383t2.jpg ATP-binding site/ATP-competitive FDA approved/Frontline therapy
dasatinib (Sprycel) graphic file with name nihms666383t3.jpg ATP-binding site/ATP-competitive FDA approved/Frontline therapy
bosutinib (Bosulif) graphic file with name nihms666383t4.jpg ATP-binding site/ATP-competitive FDA approved/2nd-line therapy
ponatinib (Iclusig) graphic file with name nihms666383t5.jpg ATP-binding site/ATP-competitive FDA approved/2nd-line therapy
ABL001 (Currently proprietary) Myristate pocket/Allosteric Phase I/2nd-line therapy